Correlations Between Cytogenetic and Molecular Monitoring Among Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Size: px
Start display at page:

Download "Correlations Between Cytogenetic and Molecular Monitoring Among Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase"

Transcription

1 Originl Articles Correltions Between Cytogenetic nd Moleculr Monitoring Among Ptients With Newly Dignosed Chronic Myeloid Leukemi in Chronic Phse Post Hoc Anlyses of the Rtionle nd Insight for Gleevec High-Dose Therpy Study Luke P. Akrd, MD; Jorge E. Cortes, MD; Mher Albitr, MD; Sturt L. Goldberg, MD; Ghulm Wrsi, PhD; Meir Wetzler, MD; Solveig G. Ericson, MD; Jerld P. Rdich, MD Accepted for publiction October 23, Published s n Erly Online Relese December 5, From the Indin Blood nd Mrrow Trnsplnttion, Stem Cell Trnsplnttion Progrm, St. Frncis Hospitl nd Helth Centers, Indinpolis, Indin (Dr Akrd); the Deprtment of Leukemi, The University of Texs MD Anderson Cncer Center, Houston (Dr Cortes); the Deprtments of Oncology/Hemtopthology nd Reserch nd Development, NeoGenomics Lbortories, Irvine, Cliforni (Dr Albitr); the Division of Leukemi, John Theurer Cncer Center t Hckensck University Medicl Center, Hckensck, New Jersey (Dr Goldberg); Biosttistics (Dr Wrsi) nd Oncology Clinicl Development (Dr Ericson), Novrtis Phrmceuticls Corportion, Est Hnover, New Jersey; the Deprtment of Medicine, Roswell Prk Cncer Institute, Bufflo, New York (Dr Wetzler); nd the Clinicl Reserch Division, Fred Hutchinson Cncer Reserch Center, Settle, Wshington (Dr Rdich). Dr Akrd received reserch support from ARIAD Phrmceuticls, Inc (Cmbridge, Msschusetts), Pfizer Lbs (New York, New York), Tev Phrmceuticl Industries Ltd (North Wles, Pennsylvni), nd Novrtis Phrmceuticls Corportion nd is on the speker bureus for ARIAD Phrmceuticls, Inc, Bristol Myers Squibb (Princeton, New Jersey), Pfizer Lbs, Novrtis Phrmceuticls Corportion, nd Tev Phrmceuticl Industries Ltd. Dr Albitr ws n employee of Quest Dignostics t the time of the study in the Oncology/Hemtopthology nd Reserch nd Development Deprtments, Nichols Institute, Quest Dignostics, Sn Jun Cpistrno, Cliforni, nd is currently employed by Neogenomics Lbortories, Irvine, Cliforni, in the Reserch nd Development Deprtment. Dr Goldberg is on the speker bureus for ARIAD Phrmceuticls, Inc, Bristol Myers Squibb, nd Novrtis Phrmceuticls Corportion. Dr Wrsi is n employee nd stockholder of Novrtis Phrmceuticls Corportion. Dr Ericson is n employee nd stockholder of Novrtis Phrmceuticls Corportion. Dr Rdich is reserch contrctor with Novrtis Phrmceuticls Corportion nd does consulting for Novrtis Phrmceuticls Corportion, Bristol Myers Squibb, Pfizer Lbs, nd ARIAD Phrmceuticls, Inc. The other uthors, Dr Cortes nd Dr Wetzler, hve no relevnt finncil interest in the products or compnies described in this rticle. The results of the post hoc nlysis were previously presented t the 14th Interntionl Conference of the Europen School of Hemtology Interntionl Chronic Myeloid Leukemi Foundtion on September 21, 2012, in Bltimore, Mrylnd, s poster presenttion nd on September 22, 2012, s brief orl communiction. Funding for this work ws provided by Novrtis Phrmceuticls Corportion (Est Hnover, New Jersey). Reprints: Luke P. Akrd, MD, Indin Blood nd Mrrow Trnsplnttion, Stem Cell Trnsplnttion Progrm, St Frncis Hospitl nd Helth Centers, Indinpolis, IN (e-mil: lkrd@ibmtindy.com). Context. Although bone mrrow (BM) kryotyping hs been the stndrd in monitoring ptients with chronic myeloid leukemi, peripherl blood (PB) monitoring methods my be more convenient. Objective. To conduct post hoc nlyses of the Rtionle nd Insight for Gleevec High-Dose Therpy study to evlute correltions between results of cytogenetic testing nd moleculr monitoring from BM nd PB during the first 18 months of high-dose imtinib therpy, nd between erly nd lte moleculr responses. Design. Newly dignosed ptients with chronic-phse chronic myeloid leukemi received imtinib 400 mg twice dily nd were monitored qurterly for up to 18 months. Cytogenetic testing ws performed by kryotyping using BM or by fluorescence in situ hybridiztion using PB. Moleculr testing ws performed by quntittive reverse trnscriptse polymerse chin rection using BM nd PB. Results. Significnt pirwise correltions were found between results obtined by kryotyping, fluorescence in situ hybridiztion, nd quntittive reverse trnscriptse polymerse chin rection using PB or BM (ll pirwise correltions.0.8; P,.001). At 12 months, cytogenetic response by kryotyping correlted well with response by fluorescence in situ hybridiztion. A medin log reduction in BCR-ABL1 level from stndrdized bseline correlted with fluorescence in situ hybridiztion negtive sttus. Ptients with greter thn 2-log reduction in BCR- ABL1 level t 3, 6, nd 9 months were more likely to chieve mjor moleculr response t 18 months thn those with 2-log reduction or less. Conclusions. Our findings support the fesibility of moleculr monitoring using PB nd suggest tht moleculr monitoring conducted t single relible reference lbortory cn dequtely trck response without invsive BM testing. Our findings re consistent with other work indicting tht erly response to imtinib predicts fvorble long-term outcome. (Arch Pthol Lb Med. 2014;138: ; doi: /rp OA) 1186 Arch Pthol Lb Med Vol 138, September 2014 Cytogenetic nd Moleculr Monitoring for CML Akrd et l

2 Stndrd tretment for chronic myeloid leukemi (CML) consists primrily of tyrosine kinse inhibitor (TKI) therpy tht trgets the BCR-ABL1 kinse, 1 the ctivity of which underlies the pthogenesis of this cncer. The BCR- ABL1 kinse is fusion protein expressed from n berrnt gene tht is formed through reciprocl trnsloction between chromosomes 9 nd 22 (the Phildelphi chromosome [Ph]). 2 Imtinib ws the first BCR-ABL1 TKI pproved for first- nd second-line tretment of CML. 3 Since then, nilotinib 4 nd dstinib 5 hve been pproved for first- nd second-line tretment of CML, nd bosutinib 6 nd pontinib 7 for second- nd subsequent-line tretment of CML. Adequte monitoring of ptient response to BCR-ABL1 TKI therpy is mndtory component of the successful mngement of CML. A growing body of evidence demonstrtes significnt positive correltion between the chievement of erly response to TKI therpy nd fvorble long-term outcomes, prticulrly in ptients who chieve cytogenetic nd moleculr response 3 months fter the initition of TKI therpy The Ntionl Comprehensive Cncer Network (NCCN), in its clinicl prctice guidelines for CML, nd Europen LeukemiNet both recommend monitoring response to TKI therpy every 3 months. 1 Both the NCCN nd Europen LeukemiNet mke recommendtions for inititing nd chnging TKI therpy bsed on cytogenetic response. Cytogenetic testing is typiclly done by kryotyping using bone mrrow (BM) smple obtined vi n invsive procedure. Cytogenetic testing cn lso be ssessed by fluorescence in situ hybridiztion (FISH) using BM or peripherl blood (PB) smple, but this method hs not been dequtely studied s method for monitoring response to TKI therpy. Thus, the NCCN guidelines do not recommend this pproch. 1,14 There is gret interest in identifying nd vlidting new methods to monitor response to TKI therpy tht re less invsive thn kryotyping. Moleculr testing of BCR-ABL1 trnscript levels is typiclly done by highly sensitive quntittive reverse trnscriptse polymerse chin rection (qrt-pcr) using either PB or BM smples. An interntionl scle (IS) hs been estblished tht enbles direct comprison of moleculr testing dt cross lbortories. Although the NCCN guidelines generlly support moleculr monitoring over BM cytogenetic testing, they recommend BM cytogenetic testing when ccess to IS-stndrdized qrt- PCR is not vilble nd do not recommend chnges in therpy bsed on moleculr studies lone. 1 In principle, comprison of qrt-pcr results mong lbortories not using the IS cn be mde, s long s the lbortories ech estblish bseline bsed on set of smples from newly dignosed ptients with CML prior to tretment nd the mgnitudes of log reduction from these lbortory-specific stndrdized bselines re compred. Such n pproch, however, would only llow comprison of reltive BCR- ABL1/ABL1 levels cross lbortories, wheres dopting the IS would llow comprison of bsolute trnscript levels. To estblish the fesibility of methods tht use PB smples for monitoring response to therpy, studies hve compred test results obtined by multiple methods, including kryotyping versus FISH nd kryotyping versus qrt- PCR Although overll findings suggest high level of concordnce between results obtined with methods using PB versus BM, the concordnce of results obtined by different testing methods hs been inconsistent The Rtionle nd Insight for Gleevec High-Dose Therpy (RIGHT) study evluted the effect of imtinib 400 mg twice dily on the chievement of moleculr nd cytogenetic responses in the first 18 months of therpy in 115 ptients with newly dignosed CML in chronic phse. 21 Ptients in this study hd rpid response to tretment; by 18 months, rtes of complete cytogenetic response (CCyR), mjor moleculr response (MMR; 3-log reduction in BCR-ABL1 trnscript level from stndrdized bseline), nd complete moleculr response (undetectble BCR-ABL1 level using n ssy with 4.5-log sensitivity) were 83%, 63%, nd 55%, respectively. Given the limited number of studies compring different methods of CML monitoring, the post hoc nlyses of the RIGHT study described herein sought to determine the degree of concordnce between moleculr nd cytogenetic testing methods using PB or BM, nd the usefulness of erly response to predict future response to TKI therpy. METHODS Study Design nd Objectives The RIGHT study design hs been described previously. 21 Briefly, this ws single-rm, open-lbel, phse 2 study of high-dose imtinib (400 mg twice dily) in ptients 18 yers of ge or older with CML in chronic phse who were dignosed within 6 months of study entry nd hd received tretment for CML for no more thn 1 month, with the exception of hydroxyure nd/or ngrelide. Ptients hd Estern Coopertive Oncology Group performnce sttus of 0 to 2, nd dequte crdic nd liver function. All ptients were tken off the study t 18 months. Ptients could hve continued on imtinib, nd the dose used fter 18 months ws selected by the treting investigtor. The objectives of these post hoc nlyses of the RIGHT study were to determine the correltion between cytogenetic response s ssessed by FISH versus kryotyping, nd between cytogenetic response s determined by FISH versus moleculr response s ssessed by qrt-pcr. An dditionl objective ws to determine the correltion between BCR-ABL1 log reduction t 3, 6, nd 9 months nd rte of MMR t 18 months (1 month ¼ 4 weeks). The RIGHT study ws conducted in ccordnce with the Declrtion of Helsinki nd guidelines on good clinicl prctices. The study protocol ws pproved by the pproprite ethics committees, institutionl review bords, nd regultory orgniztions. All ptients provided written informed consent ccording to institutionl regultions. Hemtologic nd Cytogenetic Testing Hemtologic testing (neutrophil nd pltelet counts) nd cytogenetic testing (kryotyping nd FISH) were crried out t single commercil reference lbortory (Quest Dignostics, Sn Jun Cpistrno, Cliforni). Hemtologic testing ws done t screening; bseline; weeks 1, 2, nd 4; nd months 2, 3, 4, 6, 9, 12, 15, nd 18. Complete hemtologic response ws defined s bsolute neutrophil count greter thn 1500/lL, pltelet count greter thn /ll, nd no circulting blsts or extrmedullry involvement. Kryotyping ws done t screening nd month 12; FISH ws done t bseline nd months 3, 6, 9, 12, 15, nd 18 (Figure 1). At lest 20 metphse cells were nlyzed for kryotype nd t lest 500 cells for FISH. If the number of metphse cells ws insufficient for kryotyping, FISH ws used insted. The Vysis BCR/ABL1/ASS1 Tri-Color Dul Fusion FISH Probe Kit (Abbott Lbortories, Abbott Prk, Illinois) ws used; the sensitivity of the FISH probe ws 0.5%. Cytogenetic responses (for both kryotyping nd FISH) were clssified bsed on the percentge of Ph-positive metphses: CCyR (0%), prtil (PCyR; 1% 35%), mjor (0% 35%), minor (36% 65%), or miniml (66% 95%). Moleculr Testing Moleculr testing by qrt-pcr ws lso crried out by Quest Dignostics. Testing using BM cells ws done t screening nd months 12 nd 18; testing using PB cells ws done t bseline nd Arch Pthol Lb Med Vol 138, September 2014 Cytogenetic nd Moleculr Monitoring for CML Akrd et l 1187

3 Figure 1. Schedule of cytogenetic nd moleculr testing performed in the Rtionle nd Insight for Gleevec High-Dose Therpy study. Abbrevitions: BID, twice dily; BM, bone mrrow; FISH, fluorescence in situ hybridiztion; PB, peripherl blood; qrt-pcr, quntittive reverse trnscriptse polymerse chin rection. months 3, 6, 9, 12, 15, nd 18 (Figure 1). The Quest qrt-pcr ssy ws vlidted by the Rdich lbortory t the Fred Hutchinson Cncer Center, Settle, Wshington, lbortory tht is stndrdized to the IS. The Quest qrt-pcr ssy used ABL1 s the control gene; the Rdich lbortory ssy used b 2 - microglobulin. The men bseline rtio of BCR-ABL1 to ABL1 ws clculted from 113 prestudy smples tken from newly dignosed ptients enrolled in the RIGHT study in ddition to other smples ssyed in the Quest lbortory. A stndrdized bseline BCR-ABL1:ABL1 rtio of ws used to clculte log reductions of individul smples following therpy. The Quest qrt-pcr ssy ws cpble of detecting 4.5-log reduction in BCR-ABL1 trnscript level below this bseline. In this study, ptients who chieved undetectble BCR-ABL1 trnscript levels on study were either considered to hve n undefined log reduction or rbitrrily recorded s hving 10-log reduction. Correltion Between Cytogenetic nd Moleculr Testing Results The Spermn rnk correltion nlysis showed highly significnt correltion between ll pirwise comprisons of testing methods (Tble 2). The highest correltion coefficients were observed between results obtined by qrt-pcr using BM versus PB (Figure 2) nd by FISH (PB) versus kryotyping (BM). At 12 months, 83 ptients were evluble for both kryotype (BM) nd FISH (PB) testing. A comprison between the FISH results nd the kryotyping for these ptients t 12 months showed n overll concordnce in Sttisticl Methods Spermn rnk correltion ws used for ll correltions. A Spermn correltion coefficient of 1 indictes perfect correltion between results obtined by the 2 methods being compred. The P vlues re from test of the null hypothesis tht the correltion is zero ginst the lterntive hypothesis tht it is nonzero. Tble 1. Bseline Ptient Demogrphics nd Disese Chrcteristics (N ¼ 115) Medin ge (rnge), y 50 (19 81),65 yers, No. (%) 91 (79) 65 yers, No. (%) 24 (21) Sokl risk score, No. (%) Low 80 (70) Intermedite 20 (17) RESULTS High 14 (12) Ptients Missing 1 (1) Bseline ptient demogrphics nd disese chrcteristics Prior imtinib, No. (%) 19 (17) Men durtion of prior imtinib hve been described previously 21 ; selected chrcteristics re (rnge), d 19 (1 38) shown in Tble 1. Of 115 ptients enrolled, 83 (72%) Medin time from dignosis to first study dose (rnge), mo 0.96 ( ) completed the RIGHT study. The remining 32 ptients Clonl evolution, No. (%) (28%) discontinued the study becuse of dverse events (n ¼ 3 (3) Received imtinib for less thn 1 month, per protocol inclusion 10; 9%), withdrwl of consent (n ¼ 10; 9%), unstisfctory criteri. therpeutic effect (n ¼ 6; 5%), protocol violtion (n ¼ 4; 3%), b Defined s the presence of chromosoml bnormlities in ddition to deth (n ¼ 1; 1%), nd loss to follow-up (n ¼ 1; 1%). 21 the Phildelphi chromosome Arch Pthol Lb Med Vol 138, September 2014 Cytogenetic nd Moleculr Monitoring for CML Akrd et l

4 Tble 2. Pirwise Overll Correltion Between Cytogenetic nd Moleculr Testing Results Pirwise Comprtor 1 Pirwise Comprtor 2 No. of Ptients No. of Smples Correltion Coefficient P Vlue FISH (PB) Kryotyping (BM) ,.001 FISH (PB) qrt-pcr (BM) ,.001 FISH (PB) qrt-pcr (PB) ,.001 qrt-pcr (BM) Kryotyping (BM) ,.001 qrt-pcr (PB) Kryotyping (BM) ,.001 qrt-pcr (BM) qrt-pcr (PB) ,.001 Abbrevitions: BM, bone mrrow; FISH, fluorescence in situ hybridiztion; PB, peripherl blood; qrt-pcr, quntittive reverse trnscriptse polymerse chin rection. Kryotyping: percentge of Phildelphi chromosome positive cells of 20 or more cells nlyzed; FISH: percentge of positive cells of 500 or more cells nlyzed; qrt-pcr: log reduction of BCR-ABL1 from stndrdized bseline of , clculted from ll prestudy smples in the Rtionle nd Insight for Gleevec High-Dose Therpy study nd other lbortory dignostic smples. 94% of cses (Tble 3). Ninety-five percent of smples tht were negtive by kryotyping were negtive by FISH, nd 99% of smples tht were negtive by FISH were negtive by kryotyping. Ten smples were positive by FISH, but only 6 of these smples were lso positive by kryotyping. Seven smples were positive by kryotyping, nd 6 of these smples were lso positive by FISH. Correltion Between Moleculr Response nd Cytogenetic Response At 3, 6, 9, 12, nd 18 months, 21, 39, 51, 90, nd 82 ptients, respectively, were evluble for both FISH (PB) nd qrt-pcr (PB) testing. Of these evluble ptients, 18 of 21 (86%), 25 of 39 (64%), 36 of 51 (71%), 66 of 90 (73%), nd 76 of 82 ptients (93%) hd detectble BCR-ABL1 trnscript levels t the respective time points; the remining ptients hd undetectble BCR-ABL1 levels. A totl of 55 ptients with detectble trnscript levels chieved CCyR during the study, including 7 ptients with first documenttion of FISH-negtive sttus t 3 months, 12 ptients t 6 months, 14 ptients t 9 months, 21 ptients t 12 months, nd 1 ptient t 18 months (Figure 3). The medin log reductions from bseline in BCR-ABL1 level mong ptients with documented FISH-negtive sttus nd detectble BCR-ABL1 levels were t 3 months, t 6 months, t 9 months, nd t 12 months; overll medin log reduction in BCR-ABL1 ssocited with FISH negtivity ws (The ptient who chieved FISH negtivity t 18 months hd log reduction in BCR-ABL1 level t tht time.) Correltion Between Erly Moleculr Response nd Cytogenetic nd Moleculr Response t 18 Months For the nlysis of log reduction in BCR-ABL1 level nd chievement of CCyR t 18 months, 83 ptients t 3 months, 79 ptients t 6 months, nd 81 ptients t 9 months hd cytogenetic response dt t 18 months nd were evluble t ech time point (Tble 4). The likelihood of chieving CCyR t 18 months incresed with incresing mgnitude of log reduction in BCR-ABL1 level, regrdless of the time point t which erly response ws ssessed. Of the 9 ptients with less thn 1 log reduction in BCR-ABL1 level t 3 months, 5 remined t less thn 1 log reduction t 6 months, 1 hd 1- to 2-log reduction t 6 months, nd 3 hd no disese progression t 6 months. For the nlysis of log reduction in BCR-ABL1 level nd chievement of MMR t 18 months, 81 ptients t 3 months, 78 ptients t 6 months, nd 76 ptients t 9 months hd moleculr response dt t 18 months (Tble 5). The chievement of MMR t 18 months ws more likely in ptients with greter log reduction in BCR-ABL1 level, regrdless of the time point t which erly response ws ssessed. Medin log reduction in BCR-ABL1 level t 3 months ws 1.94 log for ptients who never chieved CCyR on study (n ¼ 15), log for ptients with CCyR (s determined by FISH-negtive sttus) t 3 months (n ¼ 7), 2.50 log for ptients who lter chieved CCyR (n ¼ 84), 2.73 log for ptients who lter chieved MMR (n ¼ 77), nd 2.80 log for ptients who lter chieved complete moleculr response (n ¼ 67). This pttern suggests tht log reduction in BCR-ABL1 Figure 2. Sctterplot of results of quntittive reverse trnscriptse polymerse chin rection (PCR) conducted using bone mrrow (BM) versus peripherl blood (PB). Horizontl nd verticl dshed blck lines indicte log reductions of 0 log nd 2 log in the qrt-pcr ssy. The solid blck line denotes ctul correltion. Arch Pthol Lb Med Vol 138, September 2014 Cytogenetic nd Moleculr Monitoring for CML Akrd et l 1189

5 Tble 3. Correltion Between Kryotyping nd FISH Testing t 12 Months (N ¼ 83) Kryotyping, % Phþ FISH, % þ Abbrevitions: þ, positive; FISH, fluorescence in situ hybridiztion; Ph, Phildelphi chromosome. Bold vlues represent negtive-negtive nd positive-positive correspondent results. level t 3 months my correlte with best response to imtinib tretment. COMMENT Becuse estblished clinicl prctice guidelines recommend tht response monitoring be done qurterly, interest in the vlidtion of less invsive modes of monitoring response to TKI therpy in ptients with CML is considerble. To our knowledge, the nlyses of the RIGHT study we hve conducted re the first to ssess pirwise correltions mong 4 testing methods: kryotyping (BM), FISH (PB), qrt-pcr (BM), nd qrt-pcr (PB). Pirwise comprisons of these tests show strong nd sttisticlly significnt correltion between ll pirs of comprtors, prticulrly qrt-pcr (PB versus BM) nd FISH (PB) versus kryotyping (BM) (Tble 2). In this study, PB qrt-pcr log reduction of log from study-specific stndrdized bseline correlted with FISH-negtive sttus, suggesting tht moleculr monitoring by PB might obvite the need for invsive BM testing. These findings corroborte other work showing tht qrt-pcr cn be relibly performed using either PB or BM. 17,19 They lso support the use of FISH (PB) to confirm dignosis when kryotyping (BM) is not fesible, s recommended in the NCCN guidelines. 1 Our nlysis of the concordnce between results by FISH (PB) versus kryotyping (BM) t 12 months (Tble 3) supports the concept tht FISH using 500-cell preprtion is more sensitive ssy thn kryotyping. Smples tht were wekly FISH positive (1% 5%) were more often found to be kryotype negtive thn positive, which my reflect degree of nonspecific FISH stining or suggest tht residul disese tht is detectble by FISH my be flsely chrcterized s undetectble by kryotyping. Of note, ll smples tht were modertely to strongly FISH positive (.5%) were scored positively by kryotyping. These observtions suggest threshold level of residul disese below which kryotyping is not suitble for response monitoring nd t which other, more sensitive methods should be used. Our findings support the vlue of using FISH (PB) during the initil 18 months of tretment to ssess tretment response, becuse it is s sensitive s kryotyping (BM). Becuse the reltionship between cytogenetic response nd qrt-pcr response ws lso correlted, our dt lso support the vlue of qrt-pcr s n lterntive to kryotyping (BM) for monitoring response. Thus, 2 PB monitoring techniques, FISH nd qrt-pcr, pper to offer n lterntive method to ccurtely ssess tretment response during the initil 18 months of tretment of CML without the need for BM exmintion. With respect to qrt-pcr testing, this study used commercil lbortory tht hd its methodology vlidted by reference lbortory ligned to the IS. Not ll reference lbortories report qrt- PCR test results on the IS, so the widespred pplicbility of our results to those lbortories is not cler. For lbortories not ligned to the IS, our dt support the use of FISH (PB), rther thn kryotyping (BM), in combintion with qrt- PCR (PB) to monitor response. For deeper levels of response, such s MMR, FISH (PB) is unlikely to be of vlue; in those circumstnces, qrt-pcr testing idelly ligned to the IS will prove most prcticl. Although qrt- PCR ligned to the IS, the preferred pproch, ws not used in this study, the qrt-pcr ssy ws vlidted by n ISstndrdized lbortory. Nevertheless, this spect remins limittion of this study, in the context of modern pproches to moleculr monitoring in ccordnce to the IS. We determined tht the medin log reduction in BCR- ABL1 level corresponding to FISH negtivity ws log (Figure 2). Becuse our findings lso show high degree of correltion between FISH (PB) nd kryotyping (BM), we consider FISH negtivity to represent CCyR. Work of others 8,19 hs shown correspondence between greter thn 2-log reduction in BCR-ABL1 level nd CCyR. Becuse FISH testing in the RIGHT study ws done t 3-month Figure 3. Log reduction in BCR-ABL1 level t the time of first documenttion of fluorescence in situ hybridiztion (FISH) negtive sttus mong ptients with detectble trnscript levels. Log reductions (circles) nd medin log reduction (br) of ptients with FISH-negtive sttus t 3, 6, 9, nd 12 months re shown. One ptient hd first documenttion of FISH-negtive sttus t 18 months (dt not shown); log reduction in BCR-ABL1 level for this ptient ws t tht time Arch Pthol Lb Med Vol 138, September 2014 Cytogenetic nd Moleculr Monitoring for CML Akrd et l

6 Tble 4. Log in BCR-ABL1 Level From Bseline t 3, 6, nd 9 Months nd Complete Cytogenetic Response (CCyR) t 18 Months Time on Imtinib, mo intervls, the exct time of conversion to FISH negtivity is not known. It is likely tht the log reduction in BCR-ABL1 level would be lower thn log if the exct time of conversion to FISH-negtive sttus were known. Current NCCN guidelines consider 1-log reduction in BCR-ABL1 level to be the moleculr equivlent of PCyR 1 ; however, the NCCN hs not yet estblished n equivlency between moleculr response nd CCyR. Therefore, s recommended in the NCCN guidelines, 1 ptients who do not demonstrte either prior BM-bsed CCyR or BM-/PB-bsed MMR t 12 months should undergo cytogenetic testing to determine the level of cytogenetic response. Our findings tht chievement of erly moleculr response correltes with chievement of CCyR nd MMR t 18 months (Tbles 4 nd 5, respectively) re consistent with lrge body of work showing tht erly cytogenetic or moleculr response to TKI therpy predicts significntly improved long-term outcomes. Severl studies hve shown tht chieving cytogenetic or moleculr response to TKI therpy t erlier time points confers n dvntge over Tble 5. Log in BCR-ABL1 Level From Bseline t 3, 6, nd 9 Months nd Mjor Moleculr Response (MMR) t 18 Months Time on Imtinib, mo Log Log No. of Ptients With Log No. of Ptients With Log No. (%) of Ptients With CCyR t 18 mo 3(n¼ 83 b ),1 9 4 (44) (83) (90) 6(n¼ 79 b ),1 6 2 (33) (67) (89) 9(n¼ 81 b ),1 5 0 (0) (50) (93) CCyR is defined s 0% Phildelphi chromosome positive. b Number of ptients t ech time point who hd corresponding cytogenetic response dt t 18 months; ptients not included in this nlysis were considered nonevluble becuse smples were either not collected or not suitble for nlysis. No. (%) of Ptients With MMR t 18 mo 3(n¼ 81) b,1 9 3 (33) (55) (80) 6(n¼ 78) b,1 6 0 (0) (67) (75) 9(n¼ 76) b,1 5 0 (0) (38) (76) MMR is defined s 3-log reduction in BCR-ABL1 level from stndrdized bseline of 3.797, clculted from ll prestudy smples in the Rtionle nd Insight for Gleevec High-Dose Therpy study nd other lbortory dignostic smples. b Number of ptients t ech time point who hd corresponding moleculr response dt t 18 months; ptients not included in this nlysis were considered nonevluble becuse smples were either not collected or not suitble for nlysis. chievement t lter time points. 22,23 In our nlyses, however, mong ptients who chieved greter thn 2-log reduction in BCR-ABL1 t 3, 6, or 9 months, similr proportion of ptients lter chieved CCyR or MMR t 18 months, suggesting tht the chievement of greter thn 2- log reduction t n erlier time point does not increse the likelihood of future CCyR or MMR. Other studies hve shown significnt improvements in long-term overll survivl in ptients who chieve cytogenetic or moleculr response t 3 months. 9 11,13 Becuse RIGHT ws n 18- month study, the cpcity of our nlyses to ssess the effect of erly response on long-term outcome nd survivl is limited. In conclusion, the findings of these post hoc nlyses of the RIGHT study suggest tht for mesuring response to TKI therpy in ptients with CML in chronic phse, kryotyping (BM) nd FISH (PB) re suitble methods for monitoring cytogenetic response, nd qrt-pcr using BM or PB is relible method for monitoring moleculr response. The wider use of methods tht rely on PB rther thn BM smples should limit the frequency t which ptients must undergo invsive BM biopsies. Ann Lu, PhD, nd Cludette Knight, PhrmD, of Percoltion Communictions LLC provided editoril ssistnce tht ws funded by Novrtis Phrmceuticls Corportion. References 1. Ntionl Comprehensive Cncer Network. NCCN clinicl prctice guidelines in oncology: chronic myelogenous leukemi. Version Accessed September 25, Nowell PC, Hungerford DA. Chromosome studies on norml nd leukemic humn leukocytes. J Ntl Cncer Inst. 1960;25: Gleevec (imtinib mesylte) [US prescribing informtion]. Est Hnover, NJ: Novrtis Phrmceuticls Corportion; Tsign (nilotinib) [US prescribing informtion]. Est Hnover, NJ: Novrtis Phrmceuticls Corportion; Sprycel (dstinib) [US prescribing informtion]. Princeton, NJ: Bristol Meyers Squibb Compny; Bosulif (bosutinib) [prescribing informtion]. New York, NY: Pfizer Lbs; Iclusig (pontinib) [prescribing informtion]. Cmbridge, MA: ARIAD Phrmceuticls, Inc; Brnford S, Rudzki Z, Hrper A, et l. Imtinib produces significntly superior moleculr responses compred to interferon lf plus cytrbine in ptients with newly dignosed chronic myeloid leukemi in chronic phse. Leukemi. 2003;17(12): Brummendorf TH, Kntrjin HM, Gmbcorti-Psserini C, et l. Assessment of erly moleculr response s predictor of long-term clinicl outcomes in the phse 3 BELA study. Blood (ASH Annu Meet Abstr). 2012; 120(21): Hnfstein B, Muller MC, Hehlmnn R, et l. Erly moleculr nd cytogenetic response is predictive for long-term progression-free nd overll survivl in chronic myeloid leukemi (CML). Leukemi. 2012;26(9): Hochhus A, Hughes TP, Sglio G, et l. Outcome of ptients with chronic myeloid leukemi in chronic phse (CML-CP) bsed on erly moleculr response nd fctors ssocited with erly response: 4-yer follow-up dt from ENESTND (Evluting Nilotinib Efficcy nd Sfety in Clinicl Trils Newly Dignosed Ptients). Blood (ASH Annu Meet Abstr). 2012;120(21): Mrin D, Hedgley C, Clrk RE, et l. Predictive vlue of erly moleculr response in ptients with chronic myeloid leukemi treted with first-line dstinib. Blood. 2012;120(2): Mrin D, Ibrhim AR, Lucs C, et l. Assessment of BCR-ABL1 trnscript levels t 3 months is the only requirement for predicting outcome for ptients with chronic myeloid leukemi treted with tyrosine kinse inhibitors. J Clin Oncol. 2012;30(3): Bccrni M, Deininger MW, Rosti G, et l. Europen LeukemiNet recommendtions for the mngement of chronic myeloid leukemi: Blood. 2013;122(6): Le Gouill S, Tlmnt P, Milpied N, et l. Fluorescence in situ hybridiztion on peripherl-blood specimens is relible method to evlute cytogenetic response in chronic myeloid leukemi. J Clin Oncol. 2000;18(7): Lesser ML, Dewld GW, Sison CP, Silver RT. Correltion of three methods of mesuring cytogenetic response in chronic myelocytic leukemi. Cncer Genet Cytogenet. 2002;137(2): Arch Pthol Lb Med Vol 138, September 2014 Cytogenetic nd Moleculr Monitoring for CML Akrd et l 1191

7 17. Lim L, Bernl-Mizrchi L, Sxe D, et l. Peripherl blood monitoring of chronic myeloid leukemi during tretment with imtinib, second-line gents, nd beyond. Cncer. 2011;117(6): Hochhus A, Lin F, Reiter A, et l. Quntifiction of residul disese in chronic myelogenous leukemi ptients on interferon-lph therpy by competitive polymerse chin rection. Blood. 1996;87(4): Kntrjin HM, Tlpz M, Cortes J, et l. Quntittive polymerse chin rection monitoring of BCR-ABL during therpy with imtinib mesylte (STI571; gleevec) in chronic-phse chronic myelogenous leukemi. Clin Cncer Res. 2003;9(1): Wng L, Person K, Pillitteri L, Ferguson JE, Clrk RE. Seril monitoring of BCR-ABL by peripherl blood rel-time polymerse chin rection predicts the mrrow cytogenetic response to imtinib mesylte in chronic myeloid leukemi. Br J Hemtol. 2002;118(3): Cortes JE, Kntrjin HM, Goldberg SL, et l. High-dose imtinib in newly dignosed chronic-phse chronic myeloid leukemi: high rtes of rpid cytogenetic nd moleculr responses. J Clin Oncol. 2009;27(28): Mrin D, Milojkovic D, Olvrri E, et l. Europen LeukemiNet criteri for filure or suboptiml response relibly identify ptients with CML in erly chronic phse treted with imtinib whose eventul outcome is poor. Blood. 2008;112(12): Quints-Crdm A, Kntrjin H, Jones D, et l. Delyed chievement of cytogenetic nd moleculr response is ssocited with incresed risk of progression mong ptients with chronic myeloid leukemi in erly chronic phse receiving high-dose or stndrd-dose imtinib therpy. Blood. 2009; 113(25): Arch Pthol Lb Med Vol 138, September 2014 Cytogenetic nd Moleculr Monitoring for CML Akrd et l

Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number

Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess

More information

Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA

Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,

More information

Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis

Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell

More information

CheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer

CheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn

More information

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 : PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged

More information

A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital

A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground

More information

CASE REPORT. Abstract. Introduction

CASE REPORT. Abstract. Introduction CASE REPORT Myelodysplstic Syndrome with Ph Negtive Monosomy 7 Chromosome following Trnsient Bone Mrrow Dysplsi during Imtini Tretment for Chronic Myeloid Leukemi Kori Krimt 1, Msyoshi Msuko 2, Tkshi Ushiki

More information

Opioid Use and Survival at the End of Life: A Survey of a Hospice Population

Opioid Use and Survival at the End of Life: A Survey of a Hospice Population 532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,

More information

Invasive Pneumococcal Disease Quarterly Report. July September 2017

Invasive Pneumococcal Disease Quarterly Report. July September 2017 Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report

More information

Community. Profile Lewis & Clark County. Public Health and Safety Division

Community. Profile Lewis & Clark County. Public Health and Safety Division Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl

More information

Efficacy of Sonidegib in Patients With Metastatic BCC (mbcc)

Efficacy of Sonidegib in Patients With Metastatic BCC (mbcc) AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,

More information

Community. Profile Yellowstone County. Public Health and Safety Division

Community. Profile Yellowstone County. Public Health and Safety Division Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl

More information

Community. Profile Missoula County. Public Health and Safety Division

Community. Profile Missoula County. Public Health and Safety Division Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk

More information

Community. Profile Big Horn County. Public Health and Safety Division

Community. Profile Big Horn County. Public Health and Safety Division Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl

More information

SYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT

SYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of

More information

The RUTHERFORD-2 trial in heterozygous FH: Results and implications

The RUTHERFORD-2 trial in heterozygous FH: Results and implications The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of

More information

Community. Profile Powell County. Public Health and Safety Division

Community. Profile Powell County. Public Health and Safety Division Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk

More information

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)

More information

Community. Profile Anaconda- Deer Lodge County. Public Health and Safety Division

Community. Profile Anaconda- Deer Lodge County. Public Health and Safety Division Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12

More information

Community. Profile Carter County. Public Health and Safety Division

Community. Profile Carter County. Public Health and Safety Division Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk

More information

Presented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE

Presented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,

More information

The Acute Time Course of Concurrent Activation Potentiation

The Acute Time Course of Concurrent Activation Potentiation Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette

More information

Analysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia

Analysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia 284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,

More information

The Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes

The Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes Originl Article doi: 10.4093/kdj.2010.34.3.166 pissn 1976-9180 eissn 2093-2650 The Effects of Smll Sized Rice Bowl on Crbohydrte Intke nd Dietry Ptterns in Women with Type 2 Dibetes Hee-Jung Ahn 1, *,

More information

Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic

Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of

More information

Introduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5

Introduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5 Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,

More information

IMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC

IMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,

More information

Y. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3

Y. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3 Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed

More information

Original Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:

Original Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract: Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute

More information

Comparison of three simple methods for the

Comparison of three simple methods for the J. clin. Pth. (1967), 2, 5 Comprison of three simple methods for the ssessment of 'free' thyroid hormone T. M. D. GIMLETTE1 From the Rdio-Isotope Lbortory, St. Thoms's Hospitl, London SYNOPSIS A dilysis

More information

Feeding state and age dependent changes in melaninconcentrating hormone expression in the hypothalamus of broiler chickens

Feeding state and age dependent changes in melaninconcentrating hormone expression in the hypothalamus of broiler chickens Supplementry Mterils Epub: No 2017_23 Vol. 65, 2018 https://doi.org/10.183/bp.2017_23 Regulr pper Feeding stte nd ge dependent chnges in melninconcentrting hormone expression in the hypothlmus of broiler

More information

University of Texas Health Science Center, San Antonio, San Antonio, Texas, USA

University of Texas Health Science Center, San Antonio, San Antonio, Texas, USA Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University

More information

Supplementary Online Content

Supplementary Online Content Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern

More information

EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1

EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were

More information

Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer

Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini

More information

Supplementary Online Content

Supplementary Online Content Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA

More information

Health-Related Quality of Life and Symptoms of Depression in Extremely Obese Persons Seeking Bariatric Surgery

Health-Related Quality of Life and Symptoms of Depression in Extremely Obese Persons Seeking Bariatric Surgery Oesity Surgery, 15, 3-39 Helth-Relted Qulity of Life nd Symptoms of Depression in Extremely Oese Persons Seeking Britric Surgery Anthony N. Frictore, PhD; Thoms A. Wdden, PhD; Dvid B. Srwer, PhD; Myles

More information

Recall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study

Recall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study Syddnsk Universitet Recll Bis in Childhood Atopic Diseses Among Adults in The Odense Adolescence Cohort Study Mørtz, Chrlotte G; Andersen, Klus Ejner; Bindslev-Jensen, Crsten Published in: Act Dermto-Venereologic

More information

Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience

Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience ORIGINAL ARTICLE Using prolifertive mrkers nd Oncotype DX in therpeutic decision-mking for brest cncer: the B.C. experience E. Bxter bsc,* L. Gondr btech pdc, C. Lohrisch md, S. Chi md, K. Gelmon md, M.

More information

Body mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health

Body mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health Originl Article - Sexul Dysfunction/Infertility pissn 2005-6737 eissn 2005-6745 Body mss index, wist-to-hip rtio, nd metbolic syndrome s predictors of middle-ged men's helth Jung Hyun Prk *, In-Chng Cho

More information

R Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1

R Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1 Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity

More information

EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE

EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.

More information

Addendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)

Addendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years) Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments

More information

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms

More information

27 June Bmnly L. WALTER ET AL.: RESPONSE OF CERVICAL CANCERS TO IRRADIATION

27 June Bmnly L. WALTER ET AL.: RESPONSE OF CERVICAL CANCERS TO IRRADIATION 27 June 1964 Bmnly MEDICAL JOURNAL L. WALTER ET AL.: RESPONSE OF CERVICAL CANCERS TO IRRADIATION x 1,638.) FIG. 2.-Foci of sme tumour s in Fig. 1 contining vible tumour cells with scnty cytoplsm, reltively

More information

Trends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?

Trends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion? ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public

More information

Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction

Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson

More information

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding

More information

Diabetes affects 29 million Americans, imposing a substantial

Diabetes affects 29 million Americans, imposing a substantial CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.

More information

Metformin and breast cancer stage at diagnosis: a population-based study

Metformin and breast cancer stage at diagnosis: a population-based study ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe

More information

ENERGY CONTENT OF BARLEY

ENERGY CONTENT OF BARLEY ENERGY CONTENT OF BARLEY VARIATION IN THE DIETARY ENERGY CONTENT OF BARLEY Shwn Firbirn, John Ptience, Hnk Clssen nd Ruurd Zijlstr SUMMARY Formultion of commercil pig diets requires n incresing degree

More information

The potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens

The potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic

More information

Lipase and Pancreatic Amylase Activities in Tissues and in Patients with Hyperamylasemia

Lipase and Pancreatic Amylase Activities in Tissues and in Patients with Hyperamylasemia CLINICAL CHEMISTRY Originl Article Lipse nd Pncretic Amylse Activities in Tissues nd in Ptients with Hypermylsemi FRED APPLE, PH.D, PETER BENSON, M.D., LYNNE PREESE, MT, M.B.A., STEVEN EASTEP, M.D., LAURA

More information

Patients with cancer are at an increased

Patients with cancer are at an increased Risk of Cncer-Associted Thrombosis nd Bleeding in Veterns With Mlignncy Who Are Receiving Direct Orl Anticogulnts Mtthew Stnkowicz, PhrmD; Megn Bnszynski, PhrmD, BCOP; nd Russell Crwford, BPhrm, BCOP The

More information

Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation

Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation Leukemi (1999) 13, 1383 1389 1999 Stockton Press All rights reserved 0887-6924/99 $15.00 http://www.stockton-press.co.uk/leu Monitoring of BCR-ABL expression using rel-time RT-PCR in CML fter bone mrrow

More information

Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification

Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification Hshimoto et l. BMC Phrmcology nd Toxicology (2017) 18:74 DOI 10.1186/s40360-017-0180-3 RESEARCH ARTICLE Open Access Dose-dependent effect of dptomycin on the rtificil prolongtion of prothrombin time in

More information

C reactive protein: an aid to assessment and

C reactive protein: an aid to assessment and C rective protein: n id to ssessment nd monitoring of cute pncretitis J Clin Pthol 1984;37:27-211 AD MAYR,* MJ McMAHON,* MARGART BOWN,t H COOPRt From the *University Deprtment ofsurgery, Generl Infrmry,

More information

Emerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data

Emerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic

More information

Abstract. Background. Aim. Patients and Methods. Patients. Study Design

Abstract. Background. Aim. Patients and Methods. Patients. Study Design Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.

More information

Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria

Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion

More information

Hepatitis A virus (HAV) infection contributes approximately

Hepatitis A virus (HAV) infection contributes approximately Multiple Fctors Contribute to Positive Results for Heptitis A Virus Immunoglobulin M Antibody Adnn Altoom, MD, PhD; M. Qsim Ansri, MD; Jennifer Cuthbert, MD Context. In the United Sttes, successful vccintion

More information

Input from external experts and manufacturer on the 2 nd draft project plan Stool DNA testing for early detection of colorectal cancer

Input from external experts and manufacturer on the 2 nd draft project plan Stool DNA testing for early detection of colorectal cancer Input externl experts nd mnufcturer on the 2 nd drft project pln Stool DNA testing for erly detection of colorectl cncer (Project ID:OTJA10) All s nd uthor s replies on the 2nd drft project pln Stool DNA

More information

Fat intake in patients newly diagnosed with type 2 diabetes: a 4-year follow-up study in general practice

Fat intake in patients newly diagnosed with type 2 diabetes: a 4-year follow-up study in general practice Originl ppers Ft intke in ptients newly dignosed with type 2 dibetes: 4-yer follow-up study in generl prctice Floris A vn de Lr, Eloy H vn de Lisdonk, Peter L B J Lucssen, J M H Tigchelr, Sski Meyboom,

More information

Inhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD

Inhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD CHEST Originl Reserch Inhled Corticosteroid Is Associted With n Incresed Risk of TB in Ptients With COPD Jung-Hyun Kim, MD ; Ji-Soo Prk, MD ; Kyung-Ho Kim, MD ; Hye-Cheol Jeong, MD ; Eun-Kyung Kim, MD

More information

Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population

Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population Originl Article Clinicl sttistics nlysis on the chrcteristics of pneumoconiosis of Chinese miner popultion Mei-Fng Wng 1 *, Run-Ze Li 2 *, Ying Li 2, Xue-Qin Cheng 1, Jun Yng 1, Wen Chen 3, Xing-Xing Fn

More information

Mecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert:

Mecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert: SWINE (Crbdox) Improves pig performnce in wide rnge of helth nd growing conditions The Advntge Over the yers, medicted feed dditive hs proven to be cost-effective mngement tool for improving pig performnce

More information

Effectiveness of Belt Positioning Booster Seats: An Updated Assessment

Effectiveness of Belt Positioning Booster Seats: An Updated Assessment ARTICLES Effectiveness of Belt Positioning Booster Sets: An Updted Assessment AUTHORS: Kristy B. Arbogst, PhD, Jessic S. Jermkin, DSc, Michel J. Klln, MS, b nd Dennis R. Durbin, MD, MSCE,b Center for Injury

More information

Hypertension, hyperinsulinaemia and obesity in middle-aged Finns with impaired glucose tolerance

Hypertension, hyperinsulinaemia and obesity in middle-aged Finns with impaired glucose tolerance Journl of Humn Hypertension (1998) 12, 265 269 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 ORIGINAL ARTICLE Hypertension, hyperinsulinemi nd obesity in middle-ged Finns with impired glucose

More information

Inadequate health literacy is a

Inadequate health literacy is a Testing the BRIEF Helth Litercy Screening Tool Jolie Hun, PhD, Virgini Nolnd-Dodd, PhD, MPH, Jill Vrnes, EdD, John Grhm-Pole, MD, Brbr Rienzo, PhD, nd Ptrici Donldson, RN Due to the oppressive strins lid

More information

Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus

Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus Originl Article Others Dibetes Metb J 215;39:335-341 http://dx.doi.org/1.493/dmj.215.39.4.335 pissn 2233-679 eissn 2233-687 DIABETES & METABOLISM JOURNAL Effects of 6-Month Sitgliptin Tretment on Insulin

More information

TR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:

TR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary: (2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron

More information

Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight

Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight Bone Mrrow Trnsplnttion, (1999) 23, 867 873 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of utologous peripherl blood stem cell dosing by idel

More information

CheckMate-142 Study Design

CheckMate-142 Study Design Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Thierry André, 1 Sr

More information

Start ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4

Start ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4 F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND

More information

Significance of Expression of TGF- in Pulmonary Metastasis in Non-small Cell Lung Cancer Tissues

Significance of Expression of TGF- in Pulmonary Metastasis in Non-small Cell Lung Cancer Tissues Originl Article Significnce of Expression of in Pulmonry Metstsis in Non-smll Cell Lung Cncer Tissues Hisshi Sji, Hruhiko Nkmur, Idiris Awut, Norihito Kwski, Msru Hgiwr, Akihiko Ogt, Mkoto Hosk, Tkmoto

More information

One of the most important biological mechanisms of

One of the most important biological mechanisms of Brief Report Serum Thymidine Kinse 1 Activity in the Prognosis nd Monitoring of Chemotherpy in Lung Cncer Ptients: A Brief Report Benjmin Nismn, PhD,* Hovv Nechushtn, MD, PhD,* Him Birn, MD, Hds Gntz-Sorotsky,

More information

Chilblains (pernio, perniosis) are cold-induced, painful or itching

Chilblains (pernio, perniosis) are cold-induced, painful or itching Nifedipine vs Plcebo for Tretment of Chronic Chilblins: A Rndomized Controlled Tril Ibo H. Souwer, MD 1 Jcobus H. J. Bor, BSc (Mth) 2 Pul Smits, MD, PhD 3 Antoine L. M. Lgro-Jnssen, MD, PhD 1 1 Deprtment

More information

Antiviral Therapy 2017; 22:61 70 (doi: /IMP3085)

Antiviral Therapy 2017; 22:61 70 (doi: /IMP3085) Antivirl Therpy 217; 22:61 7 (doi: 1.3851/IMP385) Originl rticle Comprison of the Abbott RelTime HCV nd Roche COBAS Ampliprep/COBAS TqMn HCV ssys for the monitoring of sofosbuvir-bsed therpy Eiichi Ogw

More information

BODY OF REPORT. SEAT0 Medic Study No. 4. Serologic Response to Tha.i Hemorrha.gic Fever Virus Infection. Project No.

BODY OF REPORT. SEAT0 Medic Study No. 4. Serologic Response to Tha.i Hemorrha.gic Fever Virus Infection. Project No. BODY OF REPORT SEAT Medic Study No. 4 Project No. 3A 2561 A 811 Tsk 1: Serologic Response to Th.i Hemorrh.gic Fever Virus Infection Mi1it.q Medicl Reserch Prgr.m S. E. Asi. Mi1it.r~ Medic.1 Rese.rch Prgr.m

More information

Summary of Package Insert 1

Summary of Package Insert 1 Summry of Pckge Insert 1 For Sttes with Non-Published Policies Indictions Non-infected prtil nd full-thickness skin ulcers due to VSU 2 of greter thn 1 month durtion nd which hve not dequtely responded

More information

Evaluation of the TEST 1 erythrocyte sedimentation rate system and intra- and inter-laboratory quality control using new latex control materials

Evaluation of the TEST 1 erythrocyte sedimentation rate system and intra- and inter-laboratory quality control using new latex control materials Clin Chem Lb Med 2010;48(7):1043 1048 2010 by Wlter de Gruyter Berlin New York. DOI 10.1515/CCLM.2010.162 Evlution of the TEST 1 erythrocyte sedimenttion rte system nd intr- nd inter-lbortory qulity control

More information

Bright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit

Bright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit Bright Futures Medicl Reference Tle 2 to 5 Dy (First Week) Visit Universl Action Metolic nd Verify documenttion of neworn metolic screening results, pproprite rescreening, nd needed follow-up. Document

More information

Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project

Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project Kidney Interntionl, Vol. 64 (2003), pp. 1120 1124 Anemi in peditric hemodilysis ptients: Results from the 2001 ESRD Clinicl Performnce Mesures Project DIANE L. FRANKENFIELD, ALICA M. NEU, BRADLEY A. WARADY,

More information

key words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous

key words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous reserch report Effect of Route of Bortezomib Administrtion on Tretment Outcomes in Previously Untreted Ptients with Multiple Myelom: A Retrospective Anlysis from US Community Oncology Prctices Robert M

More information

Rheumatoid-susceptible alleles of HLA-DRB 1 are genetically recessive to non-susceptible alleles in the progression of bone destruction in the wrists

Rheumatoid-susceptible alleles of HLA-DRB 1 are genetically recessive to non-susceptible alleles in the progression of bone destruction in the wrists Annls of the Rheumtic Diseses 1994; 53: 587-592 587 Deprtment of Orthopedic Surgery, Knsi Medicl University, Otokoym Hospitl, Kyoto, Jpn Y Tod Y Mori Deprtment of Orthopedic Surgery, Knsi Medicl University,

More information

MOLECULAR AND CLINICAL ONCOLOGY 5: , 2016

MOLECULAR AND CLINICAL ONCOLOGY 5: , 2016 MOLECULAR AND CLINICAL ONCOLOGY 5: 429-436, 2016 Improvement of survivl with postmstectomy rdiotherpy in ptients with 1-3 positive xillry lymph nodes: A systemtic review nd met-nlysis of the current literture

More information

Appendix J Environmental Justice Populations

Appendix J Environmental Justice Populations Appendix J Environmentl Justice s [This pge intentionlly left blnk] Tble of Contents REFERENCES...J-2 Pge LIST OF TABLES Pge Tble J-1: Demogrphic Overview of Bruinsburg Site Project Are... J-3 Tble J-2:

More information

The Centers for Disease

The Centers for Disease originlcontributions Evluting the HIV Continuum of Cre within Lrge Integrted Helth System by Michel J. Willims, PhrmD nd Thoms J. Dilworth, PhrmD Abstrct Objective: The primry study objective ws to describe

More information

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu

More information

Report of the Conference on Low Blood

Report of the Conference on Low Blood 1046 Report of the Conference on Low Blood Cholesterol: Mortlity Associtions Dvid Jcobs, PhD; Henry Blckburn, MD; Millicent Higgins, MD; Dwyne Reed, MD, PhD; Hiroysu Iso, MD; Grdner McMilln, MD, PhD; Jmes

More information

Age related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer

Age related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,

More information

Longitudinal Association of Maternal Attempt to Lose Weight During the Postpartum Period and Child Obesity at Age 3 Years

Longitudinal Association of Maternal Attempt to Lose Weight During the Postpartum Period and Child Obesity at Age 3 Years nture publishing group Longitudinl Assocition of Mternl Attempt to Lose Weight During the Postprtum Period nd Child Obesity t Age 3 Yers Kendrin R. Sonneville 1,2, Sheryl L. Rifs-Shimn 3, Emily Oken 3,

More information

Consumer perceptions of meat quality and shelf-life in commercially raised broilers compared to organic free range broilers

Consumer perceptions of meat quality and shelf-life in commercially raised broilers compared to organic free range broilers Consumer perceptions of met qulity nd shelf-life in commercilly rised roilers compred to orgnic free rnge roilers C.Z. ALVARADO 1 *, E. WENGER 2 nd S. F. O KEEFE 3 1 Texs Tech University, Box 42141 Luock,

More information

METHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY

METHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY METHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY 1.0 SCOPE AND APPLICATION 1.1 Method 4010 is procedure for screening solids such s soils, sludges, nd queous medi such s wste wter nd lechtes

More information

Results. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)

Results. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77) Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model

More information

Health Coaching: A Preliminary Report on the Effects in Traumatic Brain Injury/Polytrauma Patients

Health Coaching: A Preliminary Report on the Effects in Traumatic Brain Injury/Polytrauma Patients ORIGINAL RESEARCH Helth Coching: A Preliminry Report on the Effects in Trumtic Brin Injury/Polytrum Ptients Esmerld Mdrigl, MSW; Mx Gry, BA; Molly A. Timmermn, DO; Ttin Orozco, PhD; Dine Cowper Ripley,

More information

In the treatment of cardiovascular disease (CVD), national

In the treatment of cardiovascular disease (CVD), national n report n Beyond LDL Cholesterol: The Role of Elevted Triglycerides nd Low HDL Cholesterol in Residul CVD Risk Remining After Sttin Therpy Peter Algon Jr, MD, FACC In the tretment of crdiovsculr disese

More information

Summary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV)

Summary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV) Summry Effect evlution of the Rehbilittion of Drug-Addicted Offenders Act (SOV) The Rehbilittion of Drug-Addicted Offenders Act (SOV) ws lunched on April first 2001. This lw permitted the compulsory plcement

More information